ERBB2 and gastric cancer: This is somewhat easier and quicker for bright-field ISH than for FISH.26,27 It is beyond the scope of this study to establish the predictive value of the different ISH modalities in GC patients who are candidates for HER2-targeted therapies, but the use of automated ISH techniques may enable rapid screening of thousands of patients in order to determine the real predictive cut-off for clinical benefit (i.e. polysomy, degree of HER2 amplification).